HC Wainwright Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $168.00

Neurocrine Biosciences (NASDAQ:NBIX - Free Report) had its price target decreased by HC Wainwright from $185.00 to $168.00 in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Neurocrine Biosciences' Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at $0.58 EPS, Q3 2025 earnings at $1.11 EPS, Q4 2025 earnings at $1.34 EPS, FY2025 earnings at $2.79 EPS, FY2026 earnings at $4.33 EPS, FY2027 earnings at $7.09 EPS, FY2028 earnings at $10.82 EPS and FY2029 earnings at $14.31 EPS.

Other equities analysts have also issued reports about the stock. Barclays lifted their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an "overweight" rating in a research report on Monday, December 23rd. JPMorgan Chase & Co. lifted their target price on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a report on Wednesday, March 26th. Piper Sandler reiterated an "overweight" rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a research report on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price objective for the company. Finally, Morgan Stanley reiterated an "overweight" rating and set a $150.00 target price (down previously from $185.00) on shares of Neurocrine Biosciences in a research report on Friday, March 7th. Three equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $161.14.

Neurocrine Biosciences Trading Up 0.9 %

Shares of NBIX traded up $0.97 during mid-day trading on Tuesday, hitting $106.73. 1,328,294 shares of the company's stock were exchanged, compared to its average volume of 1,066,883. Neurocrine Biosciences has a fifty-two week low of $84.23 and a fifty-two week high of $157.98. The business's 50 day moving average is $107.16 and its two-hundred day moving average is $122.08. The firm has a market capitalization of $10.56 billion, a P/E ratio of 32.44, a P/E/G ratio of 0.77 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. On average, equities research analysts forecast that Neurocrine Biosciences will post 4.28 earnings per share for the current year.

Neurocrine Biosciences announced that its board has approved a stock repurchase plan on Friday, February 21st that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the company to reacquire up to 4.2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

Insider Activity at Neurocrine Biosciences

In other news, insider Julie Cooke sold 1,551 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.78, for a total transaction of $181,125.78. Following the completion of the sale, the insider now owns 19,544 shares of the company's stock, valued at approximately $2,282,348.32. This trade represents a 7.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kevin Charles Gorman sold 5,844 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $116.69, for a total transaction of $681,936.36. Following the completion of the sale, the director now owns 521,618 shares in the company, valued at approximately $60,867,604.42. This trade represents a 1.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 167,906 shares of company stock worth $24,671,530. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in Neurocrine Biosciences during the 4th quarter worth $25,000. Huntington National Bank raised its stake in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after buying an additional 97 shares in the last quarter. Brooklyn Investment Group lifted its holdings in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after acquiring an additional 115 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in Neurocrine Biosciences in the first quarter worth approximately $34,000. Finally, GeoWealth Management LLC raised its position in shares of Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after purchasing an additional 102 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.